



---

## *Clinical Laboratory and Pathology Services*

May 12, 2021

### **Attention Oncologists**

### **RE: Testing Modifications (Monoclonal Protein Study)**

Mayo Laboratories has discontinued the Monoclonal Protein Study used when requesting a Serum Protein Electrophoresis and Immunofixation or Immunoelectrophoresis.

### **There are 3 choices in our Laboratory Collection Manual to replace this test:**

**PEISO** - Protein Electrophoresis and Isotype, Serum

<https://beebehealthcare.org/testcatalog/show/PEISO>

This test includes total protein, serum protein electrophoresis, and M-protein Isotype MALDI-TOF MS

**TMOGA** - Monoclonal Gammopathy, Serum

<https://beebehealthcare.org/testcatalog/show/TMOGA>

This test is **not recommended** to screen or establish a first-time diagnosis for a monoclonal gammopathy. It is used for **monitoring patients** with monoclonal gammopathies.

**DMOGA** - Monoclonal Gammopathy Diagnostic, S

<https://beebehealthcare.org/testcatalog/show/DMOGA>

Screening and diagnosis of monoclonal gammopathies including analysis of free light chains. Assessing the risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma.

### **Testing Algorithms**

[https://www.mayocliniclabs.com/it-mmfiles/Laboratory Approach to the Diagnosis of Amyloidosis.pdf](https://www.mayocliniclabs.com/it-mmfiles/Laboratory%20Approach%20to%20the%20Diagnosis%20of%20Amyloidosis.pdf)

[https://www.mayocliniclabs.com/it-](https://www.mayocliniclabs.com/it-mmfiles/Laboratory%20Screening%20Tests%20for%20Suspected%20Multiple%20Myeloma.pdf)

[mmfiles/Laboratory Screening Tests for Suspected Multiple Myeloma.pdf](https://www.mayocliniclabs.com/it-mmfiles/Laboratory%20Screening%20Tests%20for%20Suspected%20Multiple%20Myeloma.pdf)

### **Ordering Information Requirements**

Be specific when ordering these tests:

For **screening** order PEISO or DMOGA.

For **monitoring** of patients already diagnosed with Monoclonal Gammopathy order TMOGA

### **Therapeutic Antibodies**

You are required to indicate any therapeutic antibodies being administered. Please use the attached checklist to indicate the antibodies. When you do not supply this information results can delay patient care and outcomes.

We appreciate your review of this information. Feel free to contact me if you have questions.

A handwritten signature in black ink, appearing to read 'Xiaoli Chen', is written over a white background.

Xiaoli Chen, MD, MBA

Chairman and Medical Director, Clinical Laboratory and Pathology Services

Beebe Healthcare

302-645-3595

[xchen@beebehealthcare.org](mailto:xchen@beebehealthcare.org)

